(firstQuint)Phase 3 Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027).

 The study had a Screening period (minimum of 7 days and up to approximately 14 days) to determine participant inclusion, a Baseline visit including 24 hours of objective measurement of cough.

 The study had two treatment periods (a main 12-week treatment period and a 40-week extension period), and a 14-day follow-up period.

.

 Phase 3 Study of Gefapixant (MK-7264) in Adult Participants With Chronic Cough (MK-7264-027)@highlight

The primary objective of this study was to evaluate the efficacy of gefapixant in reducing cough frequency as measured over a 24-hour period.

